Ocugen Inc. [NASDAQ: OCGN] closed the trading session at $5.64 on 04/19/21. The day’s price range saw the stock hit a low of $5.29, while the highest price level was $5.93. The company report on April 14, 2021 that Ocugen Inc. Announces John Paul Gabriel as Senior Vice President, Manufacturing and Supply Chain.
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, announced that John Paul (J.P.) Gabriel will be joining as Senior Vice President (SVP), Manufacturing and Supply Chain.
John Paul (J.P.) Gabriel is a seasoned biopharmaceutical manufacturing professional with over 25 years of industry experience. Over the course of his career, Mr. Gabriel has held leadership positions with Sanofi Pasteur (formerly Connaught Laboratories), Pfizer Vaccines (formerly Wyeth), Genentech/Roche, and most recently with Ultragenyx Pharmaceutical, where he was Vice President of Biologics and mRNA Manufacturing.
The stocks have a year to date performance of 208.20 percent and weekly performance of -15.57 percent. The stock has been moved at 1635.38 percent over the last six months. The stock has performed -36.63 percent around the most recent 30 days and changed 154.05 percent over the most recent 3-months.
If compared to the average trading volume of 57.26M shares, OCGN reached to a volume of 12221891 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Ocugen Inc. [OCGN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for OCGN shares is $9.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on OCGN stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Chardan Capital Markets have made an estimate for Ocugen Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on February 09, 2021. The new note on the price target was released on February 04, 2021, representing the official price target for Ocugen Inc. stock.
The Average True Range (ATR) for Ocugen Inc. is set at 0.83, with the Price to Sales ratio for OCGN stock in the period of the last 12 months amounting to 26482.33. The Price to Book ratio for the last quarter was 43.38, with the Price to Cash per share for the same quarter was set at 0.12.
OCGN stock trade performance evaluation
Ocugen Inc. [OCGN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -15.57. With this latest performance, OCGN shares dropped by -36.63% in over the last four-week period, additionally plugging by 1635.38% over the last 6 months – not to mention a rise of 1112.90% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for OCGN stock in for the last two-week period is set at 35.41, with the RSI for the last a single of trading hit 27.17, and the three-weeks RSI is set at 41.36 for Ocugen Inc. [OCGN]. The present Moving Average for the last 50 days of trading for this stock 8.58, while it was recorded at 6.24 for the last single week of trading, and 2.69 for the last 200 days.
Ocugen Inc. [OCGN]: An insightful look at the core fundamentals
Ocugen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.20 and a Current Ratio set at 7.20.
Earnings per share (EPS) analysis for Ocugen Inc. [OCGN] stock
With the latest financial reports released by the company, Ocugen Inc. posted -0.07/share EPS, while the average EPS was predicted by analysts to be reported at -0.05/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -40.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for OCGN.
Ocugen Inc. [OCGN]: Insider Ownership positions
There are presently around $82 million, or 7.70% of OCGN stock, in the hands of institutional investors. The top three institutional holders of OCGN stocks are: VANGUARD GROUP INC with ownership of 9,074,993, which is approximately 22.016% of the company’s market cap and around 2.86% of the total institutional ownership; BLACKROCK INC., holding 2,225,674 shares of the stock with an approximate value of $12.55 million in OCGN stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $6.86 million in OCGN stock with ownership of nearly 123.056% of the company’s market capitalization.
35 institutional holders increased their position in Ocugen Inc. [NASDAQ:OCGN] by around 3,866,099 shares. Additionally, 9 investors decreased positions by around 3,188,865 shares, while 4 investors held positions by with 7,475,270 shares. The mentioned changes placed institutional holdings at 14,530,234 shares, according to the latest SEC report filing. OCGN stock had 28 new institutional investments in for a total of 1,312,759 shares, while 5 institutional investors sold positions of 42,673 shares during the same period.